Other Announcements & Disclosures

Biocon / Investor Relations / Stock Exchange Disclosures / Other Announcements & Disclosures

OTHER ANNOUNCEMENTS & DISCLOSURES

STOCK EXCHANGE DISCLOSURES Notice of Board Meeting Investor Meeting Press Release Company Statement Shareholding Pattern Corporate Governance Report Newspaper Advertisement RPT Disclosure Other Announcements and Disclosures

FY 2022 - 23

May-22
12-May	SEBI Listing Regulations – Disclosure of related party transactions for the half-year ended March 31. 2022
06-May	Q4 FY22 – Earnings Call Transcript
Apr-22
28-Apr	Q4 FY22 – Investor Presentation With Earnings Call Recording Link
28-Apr	Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2022

FY 2021 - 22

Mar-22
11-Mar	Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from ICRA
09-Mar	Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations. – Rating Letter from CRISIL
Feb-22
28-Feb	Investor Presentation on “Biocon Biologics to acquire Viatris’ Biosimilars Business”.
07-Feb	Biocon Pharma Limited receives U.S. FDA approval for its Posaconazole Delayed-Release tablets ANDA
Jan-22
20-Jan	Q3 FY22 – Investor Presentation
20-Jan	Outcome of the Board Meeting – Financial Results Q3 FY22 for the quarter and nine months ended December 31, 2021
03-Jan	Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dec-21
02-Dec	Biocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Mycophenolic Acid from the US FDA.
Nov-21
19-Nov	Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
04-Nov	Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
02-Nov	Q2 FY22 – Investor Presentation
Oct-21
21-Oct	Outcome of the Board Meeting – Financial Results for the quarter and half year ended September 30, 2021
04-Oct	Kiran Mazumdar Shaw’s Notification to Stock Exchanges
Sep-21
30-Sep	Query on announcement dated September 16, 2021, regarding merger of Covidshield Technologies Private Limited with, and into Biocon Biologics Limited.
July-21
24-July	Re-appointment of Directors and Auditors of the Company
24-July	Outcome of 43rd Annual General Meeting
24-July	Scrutinizer’s report and Voting Results of 43rd AGM
23-July	Change in Directorate of the Company.
22-July	Outcome of Board Meeting – Financial Results for the quarter ended June 30, 2021;
June-21
30-June	Corporate governance report for the quarter ended june 30, 2021

FY 2020 - 21

May-21
19-May	Investor Presentation – Q4 FY-21
03-May	Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures.
Apr-21
28-Apr	Change in Key Managerial Personnel of the Company.
28-Apr	Allotment of equity shares to Biocon India Limited Employee Welfare Trust under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2020-24.
28-Apr	Outcome of Board Meeting – Financial Results for the quarter and year ended March 31, 2021
24-Apr	Annual Secretarial Compliance Report
01-Apr	Investor Presentation – Q3 FY-21
Mar-21
19-Mar	Intimation for Incorporation of Wholly Owned Subsidiary Company
08-Mar	Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).
Jan-21
21-Jan	Outcome of Board Meeting – Financial Results Q3 FY21 for the quarter and nine months ended December 31, 2020
Dec-20
09-Dec	Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Oct-20
22-Oct	Outcome of Board Meeting – Financial Results for the quarter and half year ended September 30, 2020
Sep-20
22-Sep	Appointment of Mr. Anupam Jindal as Chief Financial Officer and Step down of Mr. Indranil Sen as Interim CFO
03-Sep	Allotment of shares by BBIL to Tata Capital
Aug-20
21-Aug	Intimation pursuant to Regulation 30 of SEBI Listing Regulations, amendment in Memorandum of Association of the Company
Jul-20
25-Jul	Voting results and scrutinizers’ report of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
25-Jul	Proceedings of the 42nd Annual General Meeting (‘AGM’) of Biocon Limited (‘the Company’)
23-Jul	Outcome of the Board Meeting
02-Jul	Notice of 42nd Annual General Meeting and the Annual Report for the FY 2019-20.
May-20
14-May	Outcome of the Board Meeting
14-May	Appointment of Interim Chief Financial Officer (‘Interim CFO’) and Key Managerial Personnel of the Company
Jan-20
23-Jan	Outcome of the Board Meeting

OTHER ANNOUNCEMENTS & DISCLOSURES

FY 2022 - 23

FY 2021 - 22

FY 2020 - 21

NOVEL BIOLOGICS

BIOSIMILARS

RESEARCH SERVICES

OUR CULTURE

BIOCON FOUNDATION